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Background: Despite their limited licensed indications, anti–interleukin-1 (anti–IL-1) agents are often used in
clinical practice for an increasing number of auto-inflammatory diseases. We conducted a national cross-sectional
observational study from January 2011 to January 2013 to record the off-label use of such agents in France. We
aimed to estimate the off-label use of anti–IL-1 treatments in France, assess their efficacy in rare diseases, and
increase the reporting of their possible side effects.
Methods: Physicians answered a questionnaire that covered patient and disease data, anti–IL-1 agent use, efficacy
and adverse events. The study involved adult or paediatric patient who had received an anti–IL-1 agent after
January 2005 in France.
Results: In total, 189 patients from 38 centres were included. The main diseases were adult-onset Still’s disease
(AOSD) (35), gout (28), systemic juvenile idiopathic arthritis (27), cryopyrin-associated periodic syndrome (CAPS) (21),
familial Mediterranean fever (14) and mevalonate kinase deficiency (12). The main off-label used agent was anakinra,
used at least once for 185 patients, with canakinumab used for 25. Anakinra was effective in most patients (90%),
with higher complete clinical response rates for Schnitzler’s syndrome, gout, CAPS and AOSD. Overall, 58% of
patients showed at least one adverse event, mainly minor injection-site reactions. The main reported serious
adverse event was severe infection. Injection-site reactions and liver toxicity were significantly more frequent in children
than adults. The main non-cutaneous adverse event was liver toxicity, significantly associated with treatment duration.
Weight gain was reported in about 10% of patients and was associated with treatment duration and CAPS. Canakinumab
was rarely used and showed better cutaneous tolerance than anakinra but similar rates of non-cutaneous and severe
adverse events.
Conclusions: Anakinra was well tolerated and effective in most patients with various inflammatory diseases. The main
adverse events were mild injection-site reactions, especially in children. The survey allowed for collecting limited
information on the off-label use of canakinumab.
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The auto-inflammatory diseases (AIDs) cover a wide
spectrum of systemic inflammatory diseases ranging
from rare Mendelian to polygenic disorders whose
pathogenesis lies in deregulation of interleukin-1 beta
(IL-1β) secretion [1,2]. The diseases manifest as recur-
rent fevers, variously affecting other organs such as
joints, skin, eyes, nervous system and serous tissues.
Levels of acute-phase reactants are markedly elevated
during flares and classically disappear (or are markedly
reduced) in between flares. Other polygenic diseases
such as adult-onset Still’s disease (AOSD), systemic
juvenile idiopathic arthritis (sJIA), Beçhet’s disease and
gout, also belong to the AIDs, in that deregulation of
IL-1 is involved, at least in part, in their pathogenesis [3].
The use of anti–IL-1 treatments for these conditions is
continually increasing, most often in an off-label setting
and without standardized monitoring. Thus, we lack in-
formation on their medium- and long-term effectiveness
and side effects.
At present, 4 molecules have been manufactured
(Additional file 1: Table S1); 2 are available in France:
anakinra, a short half-life IL-1 receptor antagonist
(IL-1RA) approved for rheumatoid arthritis (RA) and
since November 2013 for CAPS, and canakinumab, a
long half-life monoclonal anti–IL-1β selective antibody,
approved for CAPS and for sJIA and gouty arthritis since
September and March 2013, respectively.
These drugs are given for a variety of rare diseases,
which limits the feasibility of randomised controlled tri-
als (RCTs). Therefore, we conducted a nationwide cross-
sectional observational study to describe the indications
for their off-label use and gather information about their
tolerance and efficacy. The main objectives of the study
were to 1) describe and analyse the efficacy and safety of
anti–IL-1 agents in real-life clinical practice and 2) col-
lect descriptive data on both adult and paediatric pa-
tients receiving anti–IL-1 agents in terms of the specific
diseases that led to their off-label use.
Methods
Physicians answered a questionnaire downloaded from the
website of the national scientific society “Club Rhumatisme
et Inflammation” (www.cri-net.com) that covered patient
demographics, disease data, and anti–IL-1 treatment (type,
dose, duration, effect on disease and adverse events (AEs).
Eligible patients were adult and children who had received
an off-label anti–IL-1 agent after January 2005. Physicians
provided retrospective anonymous data from medical
records, which were entered into a database.
Collected information
Collected data included patient age, gender, disease,
disease duration, clinical symptoms and signs, frequencyof attacks, inflammatory biological markers (C-reactive
protein [CRP] level before and after anti–IL-1 introduc-
tion). Other medications (disease-modifying anti-rheumatic
drugs [DMARDs] and corticosteroids) before, during and
after anti–IL-1 treatment were reported. Data on anti–IL-1
treatment included the type (name) of the drug, dose,
frequency of injections, the date of disease onset, date
and reason for discontinuation if discontinued, the ef-
fect on clinical symptoms and signs, and the occurrence
of AEs.Assessments and definitions
Response to anti–IL-1 treatment was graded as complete,
partial or failure. The evaluation was retrospective and not
standardized, but we delineated several global response
criteria, suitable for all diseases, including inflammatory
marker normalisation (CRP level < 10 mg/L). Complete
response or remission was retained when signs of active
disease were absent and inflammatory markers had nor-
malised. Partial response was retained when complete re-
sponse was not achieved but clinical improvement was
evident according to the treating physician.
Tolerance: the following AEs were specified in the
questionnaire: pain and injection-site reactions (swelling,
erythema, ecchymosis, pruritus), respiratory infections,
neutropenia (≤1000/mmc), hepatic cytolysis (2-fold the
normal value), other liver abnormalities, lipid profile
abnormalities, and other freely reported AEs. Severe in-
fections were researched and other severe AEs (SAEs)
were freely reported. We also collected information on
weight gain with anti–IL-1 treatment.Statistical analysis
Given the high variability in sample size for each disease,
general statistics are reported as both mean ± SD and
median ± interquartile range (IQR). All descriptive
results are given with 95% confidence intervals (95%
CIs). Categorical variables were compared by chi-
square test with Yates continuity correction when
required. Quantitative variables were compared by
two-sided independent-samples t test. Significance level
was set at p < 0.05. The association of s between
patient-related variables and tolerance was studied by
both univariate and multivariate analysis. For multi-
variate analysis, a stepwise logistic regression model
included all explanatory variables showing univariate
association with a p ≤ 0.2 with the dependent variables.
Variables considered clinically relevant could be included
despite the lack of univariate association. Odds ratios
(ORs) are given with 95% CIs. For stratified explanatory
variables, the chi-square test for trend was used to
study the trend for positive association with dependent
variables.
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According to our local regulations, Institutional Review
Board approval was not required for the study, but pa-
tients received detailed information on the study and
were included only if they did not agree to electronic
treatment of their data.
Results
Baseline patient characteristics
We included 189 patients (100 males), from 38 centres
(29 adult centres and 9 paediatric rheumatology centres)
(disease data in Table 1). At the time of anti–IL-1 intro-
duction, 139 patients were adults, and 50 were children or
adolescents (<18 years old). The mean age at treatment
onset for children and adolescents was 8.3 ± 4.9 years
(y), with median age 7.2 y (IQR: 12.5-3.5 = 9, total
range (TR): 17.1-0.5 = 16.6). The mean age of adult
patients was 46.6 ± 16.6 y, with median age 47.4 y
(IQR: 57.3-33.0 = 24.3; TR: 86.3-18.6 = 67.7).
The diseases were AOSD (n = 35), gout (n = 28),
sJIA (n = 27), anakinra-treated CAPS (n = 21), familial
Mediterranean fever (FMF) (n = 14), mevalonate kin-
ase deficiency (MKD) (n = 12); synovitis, acne, pustu-
losis, hyperostosis, osteitis (SAPHO) syndrome (n = 9);
Schnitzler’s syndrome (n = 7); spondyloarthritis (n = 5);
vasculitis (giant cell arteritis, n = 2; polyarteritis nodosa,
n = 2); chondrocalcinosis (n = 4); generalized pustular
psoriasis (GPP) (n = 3); tumor necrosis factor receptor-
associated periodic syndrome (TRAPS) (n = 3); relaps-
ing polychondritis (n = 3); NLRP12-asociated periodicTable 1 Baseline disease data
Disease No. of patients M/F M
AOSD 35 12/23 4
Gout 28 24/4 5
SJIA 27 17/10 7
CAPS 21 11/10 2
FMF 14 4/11 2
MKD 12 5/7 9
SAPHO 9 4/5 4
Schnitzler’s syndrome 7 5/2 5
Spondyloarthritis 5 4/1 4
Vasculitis 4 3/1 6
Chondrocalcinosis 4 1/3 6
GPP 3 2/1 5
Polychondritis 3 1/2 4
TRAPS 3 1/2 4
*At time of anti–IL-1 treatment onset.
M: male, F: female, AOSD: adult-onset Still’s disease, sJIA: systemic juvenile idiop
Mediterranean fever, MKD: mevalonate kinase deficiency, SAPHO: synovitis, acn
Vasculitis: giant cell arteritis (2) and polyarteritis nodosa (2), TRAPS: tumor necro




The main off-label anti–IL-1 agent used was anakinra,
used at least once in 185 patients. Most treated patients
received daily injections, which for a few patients in clin-
ical remission could be spaced out. All adult patients re-
ceived 100 mg/day, and children received a dose ranging
from 1 to 6 mg/kg/day. Anakinra was administered as
on-demand treatment (<15 days) in some patients with
gout (n = 12), FMF (n = 3), chondrocalcinosis (n = 1) and
neutrophilic dermatosis (n = 1).
Partial to complete efficacy was reported for 90.3% of
patients (95% CI: 85.7 to 94.3) (Table 2). Complete clin-
ical response rates varied, being higher in Schnitlzler’s
syndrome (83%), gout (78%), CAPS (72%) and AOSD
(54%). Overall, 40% of patients were still being treated at
last visit (Table 2). Inefficacy or loss of efficacy in pa-
tients with AOSD and SJIA and persistent remission in
patients with gout, were the principal reasons for ana-
kinra withdrawal. The reasons for anakinra withdrawal
and switch to canakinumab for each disease are reported
in Table 3.
Canakinumab
Canakinumab was used in 25 patients, mainly children
(18 vs. 7 adults), as second-line treatment after anakinra
for most (21). This medication was administered everyedian age* (y) (IQR, TR) Median disease duration* (y) (IQR)
0.9 (22.4, 21.4-79.4) 4.4 (7.4, 0.04-46.9)
7.4 (11.5, 29.0-86.3) 1.6 (8.5, 0.03-37.2)
.3 (9.35, 2.1-29.1) 1.4 (5.2, 0.11-24.1)
5.9 (22.5, 3.8-66.3) 20.7 (25.3, 0.5-54.7)
1.1 (33.7, 5.9-60.8) 13.1 (19.5, 5.3-42.9)
.5 (14.9, 1.4-36.1) 9.5 (15.6, 0.83-34.9).
9.1 (18.8, 25.2-59.0) 10.6 (14, 1.2-26.3)
5.3 (22.0, 49.9-76.2) 7.4 (6.2, 3.5-13.7)
4.1 (18.9, 31.2-72.5) 10.3 (7.3, 5.1-13.4)
9.5 (18.6, 58.7-83.6) 6.7 (6.1, 3.8-15.9)
7.9 (18.8, 46.8-83.6) 3.7 (2.8, 0.5-10.4)
5.5 (21.1, 44.3-72.4) 17.1 (13.4, 8.5-35.5)
2.2 (27.5, 29.8-66.4) 9.1 (10.9, 8.3-30.1)
7.8 (29.5, 12.5-51.7) 31.2 (19.1, 9.3-47.5)
athic arthritis, CAPS: cryopyrin-associated periodic syndrome, FMF: familial
e, pustulosis, hyperostosis, osteitis, GPP: generalized pustular psoriasis,
sis factor receptor-associated periodic syndrome, IQR: interquartile range,
Table 2 Anakinra efficacy by disease
Disease No. of
patients
Clinical response (available data) Median treatment
duration (days) (IQR)
Associated* treatment CCS DMARDs Still treated Associated treatment
reduction
None Partial Total
AOSD 35 3 (8.6%) 12 (34.3%) 19 (54.3%) 461 (1164) 28/34 (82.4%) 24/28 (85.7%) 26/28 (92.9%) 15/35 (42.9%) 25/34 (73.5%)
Gout 28 0 6 (21.4%) 22 (78.6%) 7 (96.5) 20/27 (74.1%) 7/20 (35%) 0 3/24 (12.5%) 22/24 (91.7%)
sJIA 26 3 (11.5%) 12 (46.2%) 11 (42.3%) 502 (1154) 22/23 (95.7%) 20/22 (90.1%) 9/22 (40.9%) 10/26 (38.5%) 22/25 (88%)
CAPS 21 0 6 (28.6%) 15 (72.4%) 1059 (1235) 7/18 (38.9%) 3/8 2/9 10/21 (47.6%) 11/13
FMF 13 1 (7.6%) 6 (46.2%) 6 (46.2%) 390 (814.5) 10/12 (83.3%) 4/12 (33.3%) 2/12 (16.7%) 7/13 (53.8) 6/9 (66.7%)
MKD 10 0 7 (70.0%) 3 (30.0%) 266 (448) 3/4 1/4 0/4 3/10 3/3
SAPHO 9 4 (44.4%) 4 (44.4%) 1 (11.1%) 86 (337) 4/8 1/4 1/4 2/9 3/6
Schnitzler’s syndrome 7 1 (16.7%) 0 5 (83.3%) 479 (1227) 4 (/5) 2/4 1/4 4/7 5/6
Spondyloarthritis 5 4 1 0 30 (10–91) 3/5 1/5 0/5 0/5 3/5
Vasculitis 4 0 2 1 424 (94–916) 3/3 3/3 1/3 2/4 3/3
Chondrocalcinosis 4 1 2 1 52 (6–227) 2/4 1/4 1/4 2/4 2/4
GPP 3 0 0 3 56 (6–129) 2/3 1/3 0/3 1/3 2/3
Polychondritis 3 0 2 1 395 (110–1961) 3/3 3/3 3/3 1/3 2/3
TRAPS 3 0 2 1 215 (29–225) 3/3 3/3 0/3 2/3 2/3
NAPS12 2 0 2 0 797 2/2 0/2 0/2 0/2 0/2
CCS: corticosteroids. AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin associated periodic syndrome, FMF: familial Mediterranean fever, MKD: mevalonate kinase deficiency,
Vasculitis: giant cell arteritis (2) and polyarteritis nodosa (2), GPP: generalized pustular psoriasis, TRAPS: tumor necrosis factor receptor-associated periodic syndrome, NAPS 12: NLRP12-associated periodic syndrome,
IQR: interquartile range.






























AOSD 20/35 14 3 1 0 2 2
Gout 18/28 0 0 17 1 0 0
SJIA 16/26 7 3 5 0 1 6
CAPS 11/21 1 1 1 0 8 3
MKD 7/10 2 2 0 0 3 4
FMF 6/13 1 3 0 1 1 3
SAPHO 7/9 5 2 0 0 0 0
Schnitzler’s syndrome 3/7 1 2 0 0 0 1
Spondylo arthritis 5/5 2 3 0 0 0 0
Vasculitis 2/4 2 0 0 0 0 2
Chondro calcinosis 2/4 1 0 1 0 0 0
TRAPS 1/3 1 0 0 0 0 0
GPP 2/3 1 0 1 0 0 0
Polychondritis 1/3 1 0 0 0 0 0
NAPS12 2/2 2 0 0 0 0 0
AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin associated periodic syndrome, FMF: familial Mediterranean fever, MKD:
mevalonate kinase deficiency, Vasculitis: giant cell arteritis (2) and polyarteritis nodosa (2), GPP: generalized pustular psoriasis, TRAPS: tumor necrosis factor
receptor-associated periodic syndrome, NAPS 12: NLRP12-associated periodic syndrome.
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tient with MKD and another with TRAPS who received
canakinumab every 4 weeks. All adult patients and ado-
lescents >40 kg received 150 mg; paediatric patients
(<40 kg) received doses ranging from 2 to 7 mg/kg.
Higher doses were administered for MKD and sJIA.
Global canakinumab efficacy was comparable to that
of anakinra: 84% of patients (95% CI: 69.6 to 98.4) were
clinical responders, and 42% (95% CI: 22.7 to 61.4) were
complete responders (Table 4). Median treatment dur-
ation was 445 days (IQR: 126–749 = 623); 60% of patients
were still receiving treatment at the last visit (Table 4).
Five patients received canakinumab after anakinra failure:
1 achieved complete clinical response, and 4 were partial
responders.Drug efficacy per disease
Overall data for drug efficacy are in Tables 2, 3 and
Additional file 1: Table S2 (single cases of AIDs) for
anakinra treatment and in Table 4 for canakinumab
treatment.Tolerance of anti–IL-1 treatment
Anakinra
Overall, 58% of patients (95% CI: 50.3-65.3) who received
anakinra experienced at least one AE. Most AEs were cu-
taneous: minor injection-site reactions (39% of patients)
and injection-site pain (36%). Another frequent AE was
liver enzymes elevation, which was reported in 14 patients(7%). Weight increase was reported as a side effect in 11%
of patients.
AEs were significantly more frequent in paediatric
than adult patients (90.2%, 95% CI: 77.5-96.1 vs 48.2%,
95% CI: 39.9-56.5, p < 0.0001) mainly because of a higher
number of injection-site reactions in paediatric than
adult patients (58.5%, 95% CI: 43.4-72.3 vs. 33.3%, 95%
CI: 25.9-41.6, p < 0.01) and pain at the injection site
(68.3%, 95% CI: 53.0-80.4 vs. 26.7%, 95% CI: 19.9-34.7,
p < 0.0001). Liver toxicity was more frequent in chil-
dren than adults (17%, 95% CI: 8.5-31.3 vs. 4.4%, 95%
CI: 2.0-9.4, p < 0.05).
Only a few patients presented mild respiratory infec-
tions (2.8%), lipid abnormalities (1.7%) and neutropenia
(1.1%). The frequency of these AEs did not differ be-
tween children and adults.
Overall, 9% of patients (CI: 5.2-13.6) presented an
SAE, mainly severe infection (5.1%), with no difference
in frequency between children and adults (12.2%, 95%
CI: 5.3-25.6 and 7.4%, 95% CI: 4.0-13.1) (Table 5). Ana-
kinra (2 mg/Kg/day, treatment duration 156 days) led to
severe toxidermia in a child with sJIA with associated
chronic myocarditis; the child died 3 days after anakinra
withdrawal due to disease flare with acute myocarditis.
An adult with Schnitzler’s syndrome received anakinra
for about 3 years, with rapid and persistent complete
clinical response. Anakinra treatment was stopped be-
cause of lower airway infection and the discovery at the
same time of oesophageal cancer. The patient died
1 month later due to oesophageal cancer for which
Table 4 Canakinumab efficacy (used in 25 patients)










AOSD 1 No 150 mg/4 wk No 148 No No No No
AoSD 2 No 150 mg/8 wk Total 31 Yes Yes No Yes
sJIA 3 No 4 mg/kg/4 wk Partial 61 Yes Yes Yes No
sJIA 4 No 150 mg/8 wk Total 499 UK UK UK No
sJIA 5 No 150 mg/4 wk No 31 Yes Yes Yes No
sJIA 6 No 4 mg/kg/4 wk Partial 28 Yes Yes No No
sJIA 7 No 3 mg/Kg/4 wk No 28 Yes Yes No No
sJIA 8 No 4 mg/kg/4 wk No 28 Yes Yes No No
sJIA 9 Yes 4 mg/kg/4 wk Partial 538 Yes Yes Yes No
FMF 10 No 2 mg/kg/8 wk Partial 731 Yes# No No Yes
FMF 11 No 2 mg/kg/8 wk Partial 1151 Yes# No No Yes
FMF 12 No 2 mg/kg/8 wk Total 589 Yes# No No Yes
FMF 13 Yes 2 mg/Kg on demand Total 966 Yes# No No Yes
MKD 14 Yes 2 mg/kg/8 wk Partial 802 Yes Yes No Yes
MKD 15 Yes 2-3* mg/kg/8 wk Partial 1112 No No No Yes
MKD 16 No 3 mg/kg/8 wk Total 1101 UK UK UK Yes
MKD 17 No 2 mg/kg/8 wk Total 957 No No No Yes
MKD 18 No 7 mg/kg/8 wk Partial 558 Yes** No No Yes
MKD 19 No 3.5 mg/kg/8 wk Total 163 UK UK UK Yes
Vasculitis 20 No 150 mg/8 wk Partial 181 Yes Yes No No
Vasculitis 21 No 150 mg/8 wk UK UK UK UK UK No
Schnitzler’s syndrome 22 No 150 mg/8 wk Partial 385 No No No Yes
TRAPS 23 No 2 mg/kg/4 wk Total 170 Yes*** No No Yes
Erdheim Chester 24 No 2 mg/kg/8 wk Partial 679 Yes Yes No Yes
Blau syndrome 25 No 150 mg/8 wk Total 390 Yes Yes No Yes
AOSD: adult onset Still’s disease; sJIA: systemic juvenile idiopathic arthritis; FMF: familial Mediterranean fever; MKD: mevalonate kinase deficiency, Vasculitis: giant
cell arteritis (2) and polyarteritis nodosa (2), TRAPS: tumor necrosis factor receptor-associated periodic syndrome.
#FMF: all patients received colchicine with canakinumab.
*MKD patient no. 15: initial dose 2 mg/kg, then augmented to 3 mg/Kg.
*MKD patient no. 18: adalimumab was associated at the time of canakinumab onset.
***TRAPS: enalapril was given with canakinumab.
CCS: corticosteroids.
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factors.
Canakinumab
Overall, 52% (95% CI: 32.9-70.1) of patients receiving
canakinumab presented at least 1 AE, mainly mild re-
spiratory infection (17%); 9% had liver toxicity, and only
4% had injection-site reactions. Other reported AEs were
eczema and mood disorders. Paediatric and adult pa-
tients did not differ in frequency and type of AEs.
Overall, 13% of patients presented at least 1 SAE
(mainly severe infections; seizures in 1 patient). One
death was reported in an adult with severe polyarteritis
nodosa. The patient was first treated with anakinra
started at 100 mg/day and increased at 200 mg/day
after 6 months (overall treatment duration 424 days),then with canakinumab at 150 mg every 8 weeks for
2 months and every 4 weeks afterwards (overall treat-
ment duration: 181 days). The patient died because of
staphylococcal pneumonia 1 month after the last cana-
kinumab injection.
Anakinra vs. canakinumab
Anakinra- and canakinumab-treated patients in the
overall population (both children and adults) did not dif-
fer in AE or SAE frequency. Conversely, more children
had an AE with anakinra (90.2%) versus canakinumab
(58.8%) (p < 0.05). This difference was related to poor
local tolerance to anakinra (pain at injection site:
68.3% vs. 6%, p < 0.0001; injection-site reaction 58.5%
vs. 0%, p < 0.0001). The 2 populations did not differ in
non-cutaneous AEs and SAEs.
Table 5 Serious adverse events (SAEs) in adults (n = 11) and paediatric patients (n = 5) receiving anakinra
Adults Children
Patient no. Disease SAE Patient no. Disease SAE
1 Gout Pulmonary abscess 1 sJIA MAS and EBV infection
2 AOSD Pneumonia 2 sJIA MAS and hepatitis
3 AOSD VZV infection 3 sJIA MAS, severe lipodystrophy and leishmaniasis*
4 AOSD MAS and infection 4 sJIA Death, toxidermia**
5 Schnitzler’s syndrome Cancer, death 5 sJIA Scarlet fever
6 MKD Severe bronchitis
7 Vasculitis Sinusitis
8 Polychondritis Cutaneous abscess and osteitis
9 Pustular dermatosis Septicemia
10 FMF Quincke oedema
11 GPP Severe cutaneous allergic reaction
AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, FMF: familial Mediterranean fever, MKD: mevalonate kinase deficiency. Vasculitis:
polyarteritis nodosa. GPP: generalized pustular psoriasis.
MAS: macrophage activation syndrome. EBV: Epstein Barr virus.
*Leishmaniasis in child no. 3 was previously published [41].
**Child no. 4 had a severe sJIA with associated chronic myocarditis; severe toxidermia developed with anakinra treatment and he died 3 days after anakinra
withdrawal due to disease flare and acute myocarditis.
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In patients treated with anakinra, the odds for developing
at least an AE were higher for paediatric patients (OR 5.1,
95% CI: 2.1 to 12.3 p < 0.001), particularly in those with
sJIA (OR 6.5, 95% CI: 1.9 to 22.7). Conversely, gout dis-
ease and background DMARDs treatment were both asso-
ciated with lower odds of AE (Table 6). On multivariable
analysis, only paediatric age, gout disease and DMARD
treatment remained associated with an AE (Table 3).
Anti–IL-1 treatment duration, associated corticosteroids
or NSAIDs, and other diseases apart from gout and sJIATable 6 Association between patient variables and the occurr
Any adverse event
Patient variables Univariate analysis Multivariate analy
OR (95% CI) p OR (95% CI)
Paediatric vs. adult 5.67 (2.37 to 13.60) 0.0001 3.27 (1.16 to 9.21)
Treatment duration 2.12 (1.15 to 3.89) 0.02 -
Background treatment:
Methotrexate 0.44 (0.21 to 0.95) 0.03 -
All DMARDs 0.47 (0.23 to 0.98) 0.04 0.27 (0.11 to 0.64)
Corticosteroids 1.17 (0.57 to 2.38) 0.68
NSAIDs 1.38 (0.58 to 3.29) 0.47
Disease:
AOSD 1.36 (0.72 to 2.57) 0.35 -
sJIA 6.53 (1.87 to 22.7) 0.004 -
Gout 0.06 (0.02 to 0.21) 0.0001 0.05 (0.001 to 0.24)
CAPS 1.37 (0.52 to 3.61) 0.53 -
OR: odds ratio. 95% CI: 95% confidence interval, DMARDs: disease-modifying anti-rh
onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin assocwere not associated with AEs. In children, different ana-
kinra daily doses were not associated with AEs (data not
shown). Daily doses did not vary in adults.
Higher than the median treatment duration increased,
while gout disease decreased, the risk of non-cutaneous
AEs (Additional file 1: Table S3). On multivariable ana-
lysis, only the association with treatment duration per-
sisted, and we found a significant trend for increased
odds of overall non-cutaneous AEs with increased
quartile of treatment duration (p = 0.05). Methotrexate
or any DMARDs background treatment did not protectence of adverse events with anakinra treatment
Non cutaneous adverse event
sis Univariate analysis Multivariate analysis
p OR (95% CI) p OR (95% CI) p
0.03 1.83 (0.90 to 3.73) 0.10 - n.s.
n.s 2.61 (1.34 to 5.13) 0.005 3.37 (1.46 to 7.80) 0.01
n.s. 0.61 (0.26 to 1.41) 0.25 - n.s.
0.003 0.72 (0.33 to 1.59) 0.42
0.82 (0.38 to 1.75) 0.62
0.67 (0.26 to 1.74) 0.41
n.s. 0.91 (0.46 to 1.79) 0.78
n.s. 1.42 (0.58 to 3.48) 0.45
0.0002 0.07 (0.01 to 0.51) 0.01 - n.s.
n.s. 1.97 (0.77 to 5.10) 0.16 - n.s.
eumatic drugs, NSAIDs : non-steroidal anti-inflammatory drugs, AOSD: adult
iated periodic syndrome. n.s.: not significant.
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SAEs on univariate analysis. No variable was related to
SAEs on multivariate analysis (Additional file 1: Table S4).
We assessed risk factors for the most frequent non-
cutaneous AEs: liver abnormalities and severe infections.
Because of the high frequency of weight gain, we also
assessed risk factors for this event. Paediatric age and
higher than the median treatment duration were associ-
ated with poor liver tolerance on both univariate and
multivariate analyses (Additional file 1: Table S4). Ana-
kinra dose and type of disease were not associated with
liver tolerance. No variables were associated with risk of
serious infections.
CAPS disease and higher than the median anakinra
treatment duration were associated with increased risk
of weight gain (Additional file 1: Table S4) on both uni-
variate and multivariate analyses.
We studied in detail the trend for increased risk of
weight gain and elevated liver enzyme levels with in-
creasing quartile of disease duration. We found a signifi-
cant trend for increased weight gain and liver toxicity
with increased quartile of disease duration (Additional
file 1: Table S5). Conversely, no trend was found be-
tween treatment duration and severe infection.
Discussion
The results of the survey support the efficacy and safety
of anakinra in everyday clinical practice for a large num-
ber of AIDs and show a different tolerance profile between
adult and paediatric patients. Canakinumab was rarely
used in our patient population. Its more convenient ad-
ministration schedule (every 4 or 8 weeks) versus daily
anakinra injections is especially suitable for diseases re-
quiring lifelong treatment, such as sJIA and MKD.
At the onset of our data repository, anti–IL-1 drugs
were not licensed for AIDs in France. Since 2005, the
use of such drugs has been reported for various rare
AIDs for which almost no clinical trials have allowed
licensing for use. We aimed to assess the magnitude of
these prescriptions and determine whether still-unknown
side effects might not have been reported to the manu-
facturers or health authorities. In addition, we wanted
to collect information on the potential effectiveness of
anti–IL-1 agents for very rare disorders, for which the
feasibility of RCTs is limited.
Despite the limitations of retrospective data collection,
this report describes the largest series of AOSD patients
receiving anakinra [4-6]. Most had some clinical re-
sponse, with a considerable proportion of complete
responses (54.3%). Although most patients were evalu-
ated as responders, about a half had discontinued
treatment at last follow-up visit, mainly due to lack or
loss of efficacy. Patients with sJIA had similar rates of
overall clinical response and treatment discontinuationfor poor efficacy despite the numerically lower rates of
complete response as compared with AOSD. Similarly,
in a randomised placebo-controlled trial [7], most sJIA
patients had a rapid and remarkable response to ana-
kinra, but loss of efficacy was observed in most over
time. In our study, anakinra was withdrawn because of
persistent remission in 5 of 16 cases. Seven sJIA patients
received canakinumab, in most cases as second-line treat-
ment after anakinra, with some clinical response in 4. Our
data show less effectiveness of canakinumab in sJIA than
in the literature [8].
All our CAPS patients received anakinra. Despite very
long disease durations (median 20.7 y), clinical response
was reported in all 21 patients, with complete response
in most (72%). These results are in agreement with those
reported in other series [9-13].
Together with the series from Ozçakar et al. [14], this
is the largest series of FMF patients receiving anakinra
(13 patients). In FMF, and in most cases of Mendelian
AIDs, the rates of clinical response were good, and
anakinra helped in reducing or discontinuing associ-
ated medications, especially corticosteroids. This find-
ing agrees with previously reported case series [15-19].
Moreover, anakinra was highly effective in Schnitzler’s
syndrome, which agrees with the literature [20-23]. The
reporting of anti–IL-1 treatment efficacy on inflammatory
dermatosis is extremely limited [24-26]. In our study, ana-
kinra was highly effective in 7 patients with GPP (3), pus-
tular dermatosis (2), deficiency of the IL-36 receptor
antagonist (1), and neutrophilic dermatosis (1).
IL-1 inhibition represents an alternative for patients
with gout with failure of or intolerance to standard medi-
cations, because the main mechanism of crystal-induced
inflammation is the activation of NLRP3 inflammasome
and the consequent excessive production of IL-1β [27].
Canakinumab was recently approved by the European
Medicines Agency for refractory gouty arthritis on the
basis of results of 2 RCTs [28]. All patients included in
our survey were responders to anakinra and almost 80%
achieved clinical remission. The drug was discontinued
because of persistent remission in most patients. The ex-
cellent response to anakinra in gouty arthritis was shown
in both outpatient series [29], and in medically complex
hospitalized patients [30].
The study provides some elements to assess the toler-
ance of anti–IL-1 agents, especially anakinra, within a
non-randomized, non-selected population of patients with
rare diseases, often with long disease duration. Moreover,
we could compare the tolerance profile of these drugs be-
tween adults and children. Overall, anakinra was well tol-
erated, with risk of at least 1 AE developing higher for
children than adults. Among paediatric patients, we did
not find any association between anakinra dose and AE
risk, but the number of children receiving high doses
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conclusions.
Pain and skin reactions at the injection site were the
main treatment-related side effects and were signifi-
cantly more frequent in children than adults. An open-
label study with anakinra for sJIA and AOSD showed a
higher number of cutaneous AEs for sJIA than AOSD,
but the sample size was too small to reach significance
[31]. Cutaneous AEs, reported in all studies with variable
frequencies (from 20% to 90%), are usually transient and
improve after the first month of treatment [7,31,32]. In
fact, drug dose or treatment duration was not associated
with cutaneous AEs. Background treatment with DMARDs,
mainly methotrexate, was associated with reduced risk of
cutaneous AE on both univariate and multivariate analyses.
To the best of our knowledge, this association had never
been reported.
The main non-cutaneous AEs were liver abnormalities
(reported apart from macrophage activation syndrome
[MAS]). Weight gain was also reported in a number of
patients. Weight gain can be considered a benefit for
some patients, such as paediatric patients, but can be
considered an AE, if excessive, in adult patients. Treat-
ment duration was the best predictor of liver abnormal-
ities and weight gain. The risk for both these events
increased significantly with longer treatment, which sup-
ports the need for monitoring weight and liver tolerance
with long-term anakinra treatment. Importantly, weight
gain, which involved 1 in 10 patients in the survey, is
not reported in the summary description for anakinra
[33]. The association of anakinra treatment duration and
liver toxicity was not demonstrated in a 3-year open-
label follow-up of a large RCT of rheumatoid arthritis
[34]. In our study, children were at increased risk of liver
abnormalities, with no difference between children and
adults in other non-cutaneous AEs or SAEs.
The most frequent SAEs were serious infection. We
found no variable associated with SAEs or serious infec-
tion except in patients with sJIA but only on univariate
analysis. The increased risk of SAE may be related to the
intrinsic disease severity, and the association with other
severe systemic disorders in this study might have been
unnoticed because of low sample size. After serious in-
fection, MAS was a frequently reported SAE. A strong
association exists between sJIA and MAS, which may be
occult in up to 50% of patients [35,36]. Hence, establish-
ing the real association between the risk of MAS and
anti–IL-1 treatment is difficult, especially in this AID.
Moreover, some cases of MAS successfully treated with
anakinra have been published [37].
Patients with gout seemed to be protected against AE
development, except SAEs. Nevertheless, after adjust-
ment for disease duration, the relationship was no longer
significant on multivariate analysis. The short treatmentduration and not the disease itself could explain the low
risk. Conversely, CAPS patients were at increased risk of
excessive weight gain with anakinra, and adjustment for
disease duration did not eliminate the association on
multivariate analysis. Therefore, the risk may not be en-
tirely justified by treatment duration, and disease-related
features may play a role [32,38,39].
The survey provides limited information on canakinu-
mab and confirms the better cutaneous tolerance as com-
pared with anakinra. The main AEs (upper and lower
respiratory infections) are consistent with that reported in
the summary description for the product [40].
The main limitation of the study is its retrospective
cross-sectional design, which limits the assessment of
causality. Moreover, physicians could report AEs that
were not mentioned in the questionnaire. This situation
may limit the reporting of mild AEs and increases the
risk of unmeasured confounding factors. Moreover, the
heterogeneity of the diseases, with the consequent lack
of standardized definitions of clinical response and the
relatively low number of patients per category of disease,
limited the assessment of efficacy. For instance, we could
not determine whether non-responders to anti–IL-1 treat-
ment might have received an insufficient dose to achieve
complete response. For patients receiving canakimumab,
the sample size limits any pertinent analysis of efficacy.
Conclusions
Our study supports the good efficacy and tolerance of
anakinra for a variety of inflammatory diseases. The
main AE events were mild injection-site reaction, more
frequent in children than adults. Treatment duration
was associated with poor liver tolerance and weight gain,
which is relevant to better define the anakinra tolerance
profile. The information on off-label use of canakinumab
is limited and warrants further investigation.
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